Michael Julius
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Julius has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Prodeus
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
1 shared publication Alessandra Ferzoco
1 shared publication- Alessandra Ferzoco
Sunnybrook Research Institute, Toronto, Ontario, Canada
1 shared publication - Amanda Sparkes
Sunnybrook Research Institute
1 shared publication André Veillette
1 shared publication- Aws Abdul-Wahid
Sunnybrook Research Institute, Toronto, Ontario, Canada
1 shared publication
Latest Publications
- Open Access
- 21 September 2017
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (18)
VISTA.COMP — an engineered checkpoint receptor agonist that potently suppresses T cell–mediated immune responses
V-domain immunoglobulin suppressor of T cell activation (VISTA) is a recently discovered immune checkpoint ligand that functions to suppress T cell activity. The therapeutic potential of activating this immune checkpoint pathway to reduce inflammatory responses remains untapped, largely due to the inability to derive agonists targeting its unknown receptor. A dimeric construct of the IgV domain of VISTA (VISTA-Fc) was shown to suppress the activation of T cells in vitro. However, this effect required its immobilization on a solid surface, suggesting that VISTA-Fc may display limited efficacy as a VISTA-receptor agonist in vivo. Herein, we have designed a stable pentameric VISTA construct (VISTA.COMP) by genetically fusing its IgV domain to the pentamerization domain from the cartilage oligomeric matrix protein (COMP). In contrast to VISTA-Fc, VISTA.COMP does not require immobilization to inhibit the proliferation of CD4 + T cells undergoing polyclonal activation. Furthermore, we show that VISTA.COMP, but not VISTA-Fc, functions as an immunosuppressive agonist in vivo capable of prolonging the survival of skin allografts in a mouse transplant model as well as rescuing mice from acute concanavalin-A–induced hepatitis. Collectively, we believe our data demonstrate that VISTA.COMP is a checkpoint receptor agonist and the first agent to our knowledge targeting the putative VISTA-receptor to suppress T cell–mediated immune responses.
- 21 September 2017
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (18)
Open AccessVISTA.COMP — an engineered checkpoint receptor agonist that potently suppresses T cell–mediated immune responses
V-domain immunoglobulin suppressor of T cell activation (VISTA) is a recently discovered immune checkpoint ligand that functions to suppress T cell activity. The therapeutic potential of activating this immune checkpoint pathway to reduce inflammatory responses remains untapped, largely due to the inability to derive agonists targeting its unknown receptor. A dimeric construct of the IgV domain of VISTA (VISTA-Fc) was shown to suppress the activation of T cells in vitro. However, this effect required its immobilization on a solid surface, suggesting that VISTA-Fc may display limited efficacy as a VISTA-receptor agonist in vivo. Herein, we have designed a stable pentameric VISTA construct (VISTA.COMP) by genetically fusing its IgV domain to the pentamerization domain from the cartilage oligomeric matrix protein (COMP). In contrast to VISTA-Fc, VISTA.COMP does not require immobilization to inhibit the proliferation of CD4 + T cells undergoing polyclonal activation. Furthermore, we show that VISTA.COMP, but not VISTA-Fc, functions as an immunosuppressive agonist in vivo capable of prolonging the survival of skin allografts in a mouse transplant model as well as rescuing mice from acute concanavalin-A–induced hepatitis. Collectively, we believe our data demonstrate that VISTA.COMP is a checkpoint receptor agonist and the first agent to our knowledge targeting the putative VISTA-receptor to suppress T cell–mediated immune responses.
- 8 June 2016
- Published by SAGE Publications in Healthcare Management Forum
- Vol. 29 (4) , 158-161
Precision medicine
Precision medicine aims to fix what is wrong with today’s healthcare: a lack of targeted interventions tailored to the person. It encompasses many aspects of health; chief among these is one’s genetic profile. Researchers are making progress as gene-sequencing technologies get better and cheaper. Although there is cause for optimism, as several initiatives at Sunnybrook Research Institute show, scientific, systemic, and logistical challenges must be surmounted before advances can be integrated into the clinic. Despite these barriers, precision medicine is the only way forward.
- 8 June 2016
- Published by SAGE Publications in Healthcare Management Forum
- Vol. 29 (4) , 158-161
Precision medicine
Precision medicine aims to fix what is wrong with today’s healthcare: a lack of targeted interventions tailored to the person. It encompasses many aspects of health; chief among these is one’s genetic profile. Researchers are making progress as gene-sequencing technologies get better and cheaper. Although there is cause for optimism, as several initiatives at Sunnybrook Research Institute show, scientific, systemic, and logistical challenges must be surmounted before advances can be integrated into the clinic. Despite these barriers, precision medicine is the only way forward.
- Open Access
- 1 September 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (39) , 26409-26422
Lck-dependent Fyn Activation Requires C Terminus-dependent Targeting of Kinase-active Lck to Lipid Rafts
- 1 September 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (39) , 26409-26422
Open AccessLck-dependent Fyn Activation Requires C Terminus-dependent Targeting of Kinase-active Lck to Lipid Rafts